Treatment of attention deficit hyperactivity disorder insomnia with blue wavelength light-blocking glasses

R. E. Fargason, Taylor Preston, Emily Hammond, R. May, K. Gamble
{"title":"Treatment of attention deficit hyperactivity disorder insomnia with blue wavelength light-blocking glasses","authors":"R. E. Fargason, Taylor Preston, Emily Hammond, R. May, K. Gamble","doi":"10.2147/CPT.S37985","DOIUrl":null,"url":null,"abstract":"Correspondence: Rachel Fargason 3rd Floor Callahan Eye Foundation Hospital, 1720 University Boulevard, Birmingham, AL 35294, USA Tel +1 205 934 4301 Fax +1 205 975 9600 Email Rfargason@uab.edu Background: The aim of this study was to examine a nonmedical treatment alternative to medication in attention deficit hyperactivity disorder (ADHD) insomnia, in which blue wavelength light-blocking glasses are worn during the evening hours to counteract the phase-delaying effect of light. Outcome measures included sleep quality and midsleep time. The capacity of ADHD subjects to comply with treatment using the glasses was assessed. Methods: Daily bedtime, wake-up time, and compliance diaries were used to assess sleep quality and timing during a baseline observation week and a 2-week intervention period. The Pittsburgh Sleep Quality Index (PSQI) was administered following baseline and intervention. The intervention protocol consisted of use of blue wavelength-blocking glasses and a moderate lighting environment during evening hours. Results: Partial and variable compliance were noted, with only 14 of 22 subjects completing the study due to nonadherence with wearing the glasses and diary completion. Despite the minimum 3-hour recommendation, glasses were worn, on average, for 2.4 hours daily. Lighting was reduced for only 58.7% of the evening. Compared with baseline, the intervention resulted in significant improvement in global PSQI scores, PSQI subcomponent scores, and sleep diary measures of morning refreshment after sleep (P = 0.037) and night-time awakenings (P = 0.015). Global PSQI scores fell from 11.15 to 4.54, dropping below the cut-off score of 5 for clinical insomnia. The more phase-delayed subjects, ie, those with an initial midsleep time after 4:15 am, trended towards an earlier midsleep time by 43.2 minutes following the intervention (P = 0.073). Participants reported less anxiety following the intervention (P = 0.048). Conclusions: Despite only partial compliance with intervention instructions, subjects completing the study showed subjectively reduced anxiety and improved sleep quality on multiple measures. The more sleep-delayed subjects trended toward an earlier sleep period following use of the glasses. Blue-blocking glasses are a potential insomnia treatment for more compliant subjects with ADHD insomnia, especially those with prominent sleep delay. Larger studies of blue light-blocking glasses in more phase-delayed groups could reveal significant advances in chronotherapeutics.","PeriodicalId":10315,"journal":{"name":"ChronoPhysiology and Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChronoPhysiology and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPT.S37985","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

Abstract

Correspondence: Rachel Fargason 3rd Floor Callahan Eye Foundation Hospital, 1720 University Boulevard, Birmingham, AL 35294, USA Tel +1 205 934 4301 Fax +1 205 975 9600 Email Rfargason@uab.edu Background: The aim of this study was to examine a nonmedical treatment alternative to medication in attention deficit hyperactivity disorder (ADHD) insomnia, in which blue wavelength light-blocking glasses are worn during the evening hours to counteract the phase-delaying effect of light. Outcome measures included sleep quality and midsleep time. The capacity of ADHD subjects to comply with treatment using the glasses was assessed. Methods: Daily bedtime, wake-up time, and compliance diaries were used to assess sleep quality and timing during a baseline observation week and a 2-week intervention period. The Pittsburgh Sleep Quality Index (PSQI) was administered following baseline and intervention. The intervention protocol consisted of use of blue wavelength-blocking glasses and a moderate lighting environment during evening hours. Results: Partial and variable compliance were noted, with only 14 of 22 subjects completing the study due to nonadherence with wearing the glasses and diary completion. Despite the minimum 3-hour recommendation, glasses were worn, on average, for 2.4 hours daily. Lighting was reduced for only 58.7% of the evening. Compared with baseline, the intervention resulted in significant improvement in global PSQI scores, PSQI subcomponent scores, and sleep diary measures of morning refreshment after sleep (P = 0.037) and night-time awakenings (P = 0.015). Global PSQI scores fell from 11.15 to 4.54, dropping below the cut-off score of 5 for clinical insomnia. The more phase-delayed subjects, ie, those with an initial midsleep time after 4:15 am, trended towards an earlier midsleep time by 43.2 minutes following the intervention (P = 0.073). Participants reported less anxiety following the intervention (P = 0.048). Conclusions: Despite only partial compliance with intervention instructions, subjects completing the study showed subjectively reduced anxiety and improved sleep quality on multiple measures. The more sleep-delayed subjects trended toward an earlier sleep period following use of the glasses. Blue-blocking glasses are a potential insomnia treatment for more compliant subjects with ADHD insomnia, especially those with prominent sleep delay. Larger studies of blue light-blocking glasses in more phase-delayed groups could reveal significant advances in chronotherapeutics.
蓝色波长遮光眼镜治疗注意缺陷多动障碍失眠
通讯:Rachel Fargason 3楼Callahan眼科基金会医院,1720大学大道,伯明翰,AL 35294,美国电话+1 205 934 4301传真+1 205 975 9600电子邮件Rfargason@uab.edu背景:本研究的目的是研究一种非药物治疗替代药物治疗注意缺陷多动障碍(ADHD)失眠,在晚上佩戴蓝色波长的阻挡光的眼镜来抵消光的相位延迟效应。结果测量包括睡眠质量和睡眠时间。评估了ADHD受试者遵守使用眼镜治疗的能力。方法:在基线观察周和2周的干预期内,使用每日就寝时间、起床时间和依从性日记来评估睡眠质量和时间。在基线和干预后给予匹兹堡睡眠质量指数(PSQI)。干预方案包括在夜间使用蓝色波长阻挡眼镜和适度的照明环境。结果:部分和可变的依从性被注意到,22名受试者中只有14名完成了研究,因为不坚持戴眼镜和完成日记。尽管建议至少戴3小时眼镜,但平均每天戴眼镜的时间为2.4小时。夜间照明减少的时间只有58.7%。与基线相比,干预导致总体PSQI评分、PSQI子成分评分和睡眠日记测量的睡眠后提神(P = 0.037)和夜间醒来(P = 0.015)显著改善。全球PSQI评分从11.15降至4.54,低于临床失眠的临界值5。阶段延迟较多的受试者,即那些最初的睡眠时间在凌晨4:15之后的受试者,在干预后倾向于提前43.2分钟的睡眠时间(P = 0.073)。干预后,参与者报告焦虑减少(P = 0.048)。结论:尽管仅部分遵守干预指示,但完成研究的受试者在多项测量中主观上显示焦虑减轻,睡眠质量改善。睡眠延迟越久的受试者在戴上眼镜后睡眠时间越早。蓝光屏蔽眼镜是一种潜在的失眠治疗方法,适用于更顺从的ADHD患者,尤其是那些睡眠明显延迟的患者。更大规模的研究表明,在更多的阶段延迟的人群中,蓝光阻挡眼镜可以揭示时间治疗的重大进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信